Bone Replacement Products Market Analysis & Forecast: 2026-2033
The Bone Replacement Products Market size is anticipated to grow at a CAGR of 6.5% with USD 4.09 Bn in 2026 and is expected to reach USD 6.35 Bn in 2033. The primary drivers are largely defined by rising demand for orthopedic implants, joint reconstruction, and trauma repair solutions across hospitals, orthopedic clinics, and ambulatory surgical centers. Some other factors include increasing prevalence of osteoarthritis, osteoporosis, sports injuries, and age-related bone degeneration. WHO reported around 1.71 Bn people live with musculoskeletal conditions globally, supporting demand for bone replacement products.
In the U.S., the rising prevalence of osteoarthritis combined with an expanding aging population is propelling a stronger demand for bone replacement products. The key products seeing increased utilization are knee implants, hip implants, tibial inserts, acetabular systems, and revision components. Osteoarthritis often causes long-term pain, stiffness, limited movement, and cartilage damage. When non-surgical treatments do not work, patients may need surgical reconstruction.
According to the CDC surveillance data from 2021, approximately 53.2 million U.S. adults, or 21.2% of the population, had doctor-diagnosed arthritis. This highlights a substantial patient base at risk of joint degeneration and replacement requirements. The aging population also accelerates the market growth, as older adults are more susceptible to bone loss, joint wear, as well as mobility limitations.
In February 2026, the FDA 510(k) documentation approved Stryker’s Triathlon X3 Medial Stabilized Tibial Bearing Insert as a sterile, single-use device for primary or revision total knee arthroplasty. This reflects ongoing innovation and thus promotes increased knee replacement procedures.
The fully personalized 3D-printed joint implants are reshaping the Bone Replacement Products Market. They allow the creation of implants precisely tailored to an individual patient’s anatomy using cutting edge imaging techniques like CT scans combined with additive manufacturing technologies. This transition from standard off-the-shelf implants to customized solutions is propelled by a rising clinical need. The degenerative joint conditions like osteoarthritis affect hundreds of millions of people across the globe.
The Global Burden of Disease Study 2020 reported that almost 595 million people suffered from osteoarthritis. This makes it one of the leading causes of disability along with a substantial driver of demand for the joint replacement. In the U.S., a major proportion of adults are affected by arthritis, thereby highlighting the potential market for improved joint reconstruction options.
In March 2025, the U.S. Food and Drug Administration (FDA) granted 510(k) clearance to Restor3D’s iTotal Identity™ CR 3DP Porous Knee Replacement System. It is a fully personalized, CT-based, additively manufactured implant specifically designed to enhance anatomical fit, alignment, and functional outcomes.
|
Current Event |
Description and its Impact |
|
U.S. FDA Quality Management System Regulation Effective from February 2026 |
|
|
CMS Proposed CJR-X Model for Hip, Knee, and Ankle Replacements |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
On the basis of product type, the knee replacement segment is projected to account for the largest Bone Replacement Products Market share of 36.5% in 2026. The segment’s growth is owing to the increasing clinical and regulatory support that reinforces its prominence.
In January 2026, the U.S. Centers for Medicare & Medicaid Services approved a pivotal Investigational Device Exemption (IDE) for a prospective, randomized trial of the BioPoly® partial resurfacing knee implant. It is specifically designed to treat focal cartilage lesions of the distal femur, thereby highlighting ongoing innovation in knee prostheses.
In addition, governmental policies are shaping the market accessibility. India’s National Pharmaceutical Pricing Authority (NPPA) extended ceiling prices for orthopedic knee replacement implants through November 15, 2026, under the Department of Pharmaceuticals guidelines, thus promoting affordability as well as patient access.
Collectively, these regulatory actions, clinical advancements, and widespread procedural uptake explain knee replacement’s leading market share within bone replacement products.
To learn more about this report, Request Free Sample
On the basis of material, the metals segment lead with a major 52.8% share in 2026. The segment’s growth is owing to the extensive clinical use of metallic implants, such as titanium and cobalt‑chromium alloys, in joint replacements and fracture fixation procedures.
Government‑aligned registries indicate that metal implants account for the majority of orthopaedic prostheses, with their prevalence rising from approximately 27% to 31.5% among U.S. adults aged 40 and above in recent years, reflecting continued reliance on metallic devices for bone and joint replacement.
Regulatory updates from the U.S. Food and Drug Administration (FDA) confirm that while traditional metal-on‑metal total hip replacement devices are no longer marketed without premarket approval, metallic components, such as cobalt‑chromium femoral heads combined with titanium stems, remain standard practice in hip arthroplasty and other procedures.
In January 2025, the FDA cleared a premarket clinical study for Silver Bullet Therapeutics’ OrthoFuzIon Bone Screw System. It is a metal‑based orthopaedic fixation solution which enables further innovation and clinical adoption of metallic implants.
To learn more about this report, Request Free Sample
The North America region accounts for 42.4% of the market share in 2026. The region’s growth is owing to the mature regulatory frameworks and high procedural volumes. Globally, an estimated 2.2 million bone graft procedures are performed annually in orthopedic, trauma, spinal, and dental applications, underscoring significant clinical demand for bone replacement materials.
In the U.S., the bone grafting materials and substitutes are regulated as medical devices with classifications ranging from Class II to Class III depending on composition, thereby ensuring safety and performance prior to market entry. For example, the synthetic and animal‑sourced grafts typically follow Class II pathways, while biologic combinations require more rigorous premarket approval.
A key development in April 2025 was the FDA granting an Investigational Device Exemption (IDE) for CGBIO’s NOVOSIS PUTTY, allowing pivotal clinical trials in spinal fusion and advancing a next‑generation bone graft substitute toward U.S. commercialization.
Asia Pacific is expected to witness strong growth in Bone Replacement Products Market over the forecast period. The region’s growth is owing to a significant and growing regional burden of osteoporosis and fragility fractures, which directly increases clinical demand for bone repair and replacement solutions.
According to the Asia Pacific Regional Audit: Epidemiology, Costs and Burden of Osteoporosis in 2025, demographic shifts and ageing across 22 countries are contributing to a surge in fracture incidence and associated surgical interventions that often require grafts and replacement materials. The data from APCO highlights that more than 50 % of global osteoporotic hip fractures are projected to occur in Asia by 2050, reflecting major pressure on bone health services and implant utilization.
In September 2024, CG Bio, a Korean regenerative medicine company, announced that it plans to strengthen its presence in China’s bone graft materials market by leveraging growing demand for synthetic bone substitutes.
The drivers of growth in the U.S. Bone Replacement Products Market include the high prevalence of osteoporosis and related fractures, with 12.6% of adults aged 50 and above affected by osteoporosis and 43.1% exhibiting low bone mass, both recognized as major risk factors for bone defects and replacement procedures, according to CDC data.
The increasing volume of orthopedic and spinal surgeries is further fueling market demand. Regulatory advancements, such as the FDA 510(k) clearance for the Adaptos Fuse bone graft substitute, have enabled its commercial launch in the U.S. for treating osseous defects.
The China Bone Replacement Products Market is growing due to the increasing prevalence of musculoskeletal disorders among the aging population, which is driving higher demand for joint and bone repair procedures.
Official data shows that over 580,000 hip and knee joint replacement sets were tendered nationwide in 2024, indicating strong procedural demand supported by public insurance schemes. In December 2025, the National Medical Products Administration (NMPA) approved 388 medical devices, including a variety of orthopedic implants, improving market availability.
A key development in January 2026 is the NMPA clearance of the Ossenhan Reverse Shoulder System, offering advanced solutions for complex shoulder reconstruction and further propelling market growth.
Some of the major key players in Bone Replacement Products Market are Zimmer Biomet Holdings, Inc., B. Braun Melsungen AG, Stryker Corporation, Smith & Nephew Plc, United Orthopedic Corporation, Depuy Synthes, Medtronic Plc., Japan Medical Dynamic Marketing, Inc., JRI Orthopedics, Exactech, Inc., and Mathys.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 4.09 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 6.5% | 2033 Value Projection: | USD 6.35 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Zimmer Biomet Holdings, Inc., B. Braun Melsungen AG, Stryker Corporation, Smith & Nephew Plc, United Orthopedic Corporation, Depuy Synthes, Medtronic Plc., Japan Medical Dynamic Marketing, Inc., JRI Orthopedics, Exactech, Inc., and Mathys. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Share
Share
Komal Dighe is a Management Consultant with over 8 years of experience in market research and consulting. She excels in managing and delivering high-quality insights and solutions in Health-tech Consulting reports. Her expertise encompasses conducting both primary and secondary research, effectively addressing client requirements, and excelling in market estimation and forecast. Her comprehensive approach ensures that clients receive thorough and accurate analyses, enabling them to make informed decisions and capitalize on market opportunities.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
